DEXCOM INC will appoint two independent directors and restructure a key board committee following an agreement with activist investor Elliott Investment Management. Shares rose 6% in after-hours trading. The board currently lacks medtech and operations expertise, an area the medical device maker is addressing as it positions for future growth.

Board Refresh Targets Operational Expertise